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In mucopolysaccharidoses (MPS), glycosaminoglycans (GAG) accumulate in tissues. In MPS II, approximately
two-thirds of patients are cognitively impaired. We investigated levels of GAG in cerebrospinal fluid (CSF) in dif-
ferent populations from four clinical studies (including NCT00920647 and NCT01449240). Data indicate that
MPS II patients with cognitive impairment have elevated levels of CSF GAG, whereas those with the attenuated
phenotype typically have levels falling between those of the cognitively affected patients and healthy controls.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Mucopolysaccharidosis II (MPS II; Hunter syndrome) is an X-linked
lysosomal storage disorder (LSD) caused by a deficiency in the enzyme
iduronate-2-sulfatase (EC 3.1.6.13), leading to the accumulation of gly-
cosaminoglycans (GAGs) in lysosomes [1]. Affected patients have
elevated levels of GAGs in serum, urine, and cerebrospinal fluid (CSF)
[2–4].
All patients with MPS II experience a variety of somatic signs and
symptoms associated with significant morbidity and early mortality
[5,6]. Approximately two-thirds of patients also displayprogressive cog-
nitive decline (severe phenotype), whereas one-third of patients re-
main cognitively intact (attenuated phenotype) [7].
Idursulfase (Elaprase®, Shire, Lexington, MA, USA), a recombinant
human iduronate-2-sulfatase, has been approved as an intravenous
(IV) medicinal product for the treatment of MPS II since 2006 in the
United States and 2007 in Europe [8]. Intravenous idursulfase does not
cross the blood–brain barrier at the therapeutic dose and is not expect-
ed to alter the cognitive decline seen in the severe phenotype [9].
Currently, limited data are available that describe the biomarker
composition of CSF [10] and quantify levels of disease-related bio-
markers present in CSF of patients with lysosomal storage diseases
[11–13]. Ongoing clinical trials are exploring drug delivery directly
into the CSF as a way of bypassing the blood–brain barrier [14].
Molecular Genetics and Metabolism Reports 5 (2015) 103–106
⁎ Corresponding author at: The Mark Holland Metabolic Unit, Salford Royal NHS
Foundation Trust, Ladywell Building, Stott Lane, Salford, M6 8HD, United Kingdom.
E-mail addresses: Chris.hendriksz@srft.nhs.uk (C.J. Hendriksz),
joseph_muenzer@med.unc.edu (J. Muenzer), avanderv@childrensnational.org
(A. Vanderver), jdavis@tuftsmedicalcenter.org (J.M. Davis), bburton@luriechildrens.org
(B.K. Burton), nancy.mendelsohn@childrensmn.org (N.J. Mendelsohn), nwang@shire.com
(N. Wang), lpan@shire.com (L. Pan), aripano@gmail.com (A. Pano), AnnJBarbier@aol.com
(A.J. Barbier).
1 Present address: Dicerna Pharmaceuticals, Inc., 87 Cambridgepark Drive, Cambridge,
MA 02421, USA.
2 Present address: Agios Pharmaceuticals, Inc., 38 Sidney Street, Cambridge, MA 02139,
USA.
http://dx.doi.org/10.1016/j.ymgmr.2015.11.001
2214-4269/© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
Molecular Genetics and Metabolism Reports
j ourna l homepage: http : / /www. journa ls .e lsev ie r .com/molecu la r -genet ics -and-
metabol i sm- repor ts /
In four studies, we investigated the levels of GAGs in the CSF to es-
tablish ranges in four types of population: healthy adults, surrogate-
normal children (childrenwho underwent a lumbar puncture for a clin-
ical indication other than suspicion of a lysosomal storage disease),MPS
II patients with cognitive impairment, and MPS II patients with no cog-
nitive impairment.
2. Material and methods
The data presented here are from four studies:
1. A phase I-II, multicenter, randomized, open-label, interventional
study of MPS II patients with cognitive involvement (HGT-HIT-045,
NCT00920647).The study investigated an idursulfase formulation
designed for intrathecal administration (idursulfase-IT). Patients
were aged b18 years, with cognitive impairment due to MPS II (IQ
b77, or IQ decline of 15–30 IQ points in past 3 years). CSF samples
were obtained at screening (prior to exposure to investigational
treatment) [15].
2. Amulticenter study of pediatric and adult patients withMPS II (HGT-
HIT-072, NCT01449240). All pediatric patientswere scheduled to un-
dergo a non-study-related lumbar puncture or othermedical or diag-
nostic procedure that required the administration of general
anesthesia duringwhich a lumbar puncture could be performed [16].
3. A single-center study of normal healthy adult volunteers undergoing
lumbar puncture (HGT-HIT-073). Patientswere ≥18 and ≤30 years of
age, and with no clinically significant findings.
4. Samples from surrogate-normal children (children fromwhom a CSF
sample was taken for a clinical indication other than suspicion of, or
in the context of, a lysosomal storage disease) were obtained from
two sources. One was a multicenter, noninterventional study of
male or female pediatric subjects (b18 years of age) undergoing a
procedure allowing access to CSF for other clinical reasons (HGT-
HIT-083). Age groups included newborns (0–27 days), infants and
toddlers (28 days to 23 months), children (2–11 years), and adoles-
cents (12 to b18 years). The second source was 157 samples from
surrogate-normal children obtained from a biorepository at The
Children's National Medical Center (CNMC) in Washington DC, and
these were analyzed with the HGT-HIT-083 samples.
Informed consentwas obtained from all patients and/or legal guard-
ians and independent review board/independent ethics committees ap-
proved all studies. Study procedures complied with Good Clinical
Practice as described in the 21 CFR Parts 50, 56, and 312 and the Inter-
national Conference on Harmonisation Guidelines, as well as with the
ethical principles described in the Declaration of Helsinki.
2.1. CSF assessment
CSF samples were evaluated for glucose, protein, albumin, and cell
counts. CSF samples were stored frozen for subsequent analysis of
total GAGs. Total CSF GAG concentrationwas determined by Shire (Lex-
ington, MA, USA) using a thrombin activity assay with chromogenic
substrate S-2238™ (Chromogenix, Bedford, MA, USA). CSF samples
were pre-incubated with a fixed amount of human heparin cofactor II
(Haematologic Technologies Inc. Essex Junction, VT, USA), then incubat-
ed with a fixed amount of Humanα-Thrombin (Enzyme Research labo-
ratories, South Bend, IN, USA) and 0.5 mM S-2238 in assay buffer. GAG
in CSF samples binds to heparin cofactor II, which in turn accelerates
thrombin inactivation. The GAG concentration was calculated from a
calibration curve prepared fromdermatan sulfate (GAG-DS01™, Iduron,
Manchester, United Kingdom) included in the same assay. The lower
limit of quantification was 36.7 ng/mL. The assay mainly detected
dermatan sulfate and heparan sulfate in the GAG family. This assay
was used to measure the CSF GAG levels for all studies reported in this
paper. The quantification of urinary GAG for HIT-045, HIT-072 and
HIT-073 was performed by Cambridge Biomedical Inc. (Boston, MA,
USA) using a Blyscan™ Glycosaminoglycan Assay kit (Biocolor Life Sci-
ence Assays, Carrickfergus, United Kingdom), and results were normal-
ized to urine creatinine [15,16].
2.2. Statistical methods
Descriptive summaries were presented for the following subject
groups: surrogate-normal children, healthy adults, cognitively-intact
MPS II patients, and cognitively-impaired MPSII patients. Data for
surrogate-normal children from study HGT-HIT-083 were merged
with those from the biorepository samples and analyzed in 4 age
groups.
3. Results
Two hundred and fifty seven subjects from the 4 studies were
assessed, and their baseline or Day 1 characteristics were measured.
Data from study HGT-HIT-072, which enrolled both cognitively intact
and cognitively impaired childrenwith MPS II, as well as cognitively in-
tact adults with MPS II are not shown separately, but per cognitive cat-
egory. For instance, the data from the 3 cognitively impaired children
whose CSF was obtained in study HGT-HIT-072 (previously published
[16]), were analyzed together with the data from the 16 cognitively im-
paired boys with MPS II from the phase I–II idursulfase-IT study (HGT-
HIT-045)(previously published [15]), leading to a total number of 19
data points for the category of cognitively affected children with MPS
II between the ages of 2–11 years.
Box plots of CSF GAG data for each subject group are shown in Fig. 1.
The average GAG level in healthy adults (n = 31) was 50.0 ± 15.5
Fig. 1. Box plots of total CSF GAG for each subject group. Notes: 1. Surrogate normal data
includes data from both the 083 study and biorepository data. 2. Values b36.7 ng/mL are
below the lower limit of quantification. Values b36.7 ng/mL are replaced with values of
36.7 ng/mL for the plot. CSF, cerebrospinal fluid; GAG, glycosaminoglycan; MPS II,
mucopolysaccharidosis II; 045, HGT-HIT-045; 072, HGT-HIT-072; 073, HGT-HIT-073;
083, HGT-HIT-083.
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ng/mL (mean±SD). In surrogate-normal children, themeanGAG levels
for neonates were 65.8± 19.3 ng/mL (n=23), for 1–23months 61.8±
27.8 ng/mL (n = 58), for 2–11 years 54.7 ± 27.2 ng/mL (n = 77), and
for 12–18 years old 51.4 ± 25.6 ng/mL (n = 43). These data indicate
that GAG levels in non-MPS II subjects were all below approximately
200 ng/mL, with means in the range of 50–70 ng/mL depending on
age. We obtained samples from two pediatric and four adult patients
withMPS IIwithout cognitive impairment, and found that the two pedi-
atric patients had values of 356.8 and 373.4 ng/mL. Of the four adult pa-
tients with the attenuated MPS II phenotype, three had levels in the
380–460 ng/mL range and one had a value of 1181.1 ng/mL. Samples
from the 19 cognitively impaired children aged 2–11 years
(representing the severe phenotype of MPS II) had average CSF GAG
levels of 1540.5 ± 859.7 ng/mL. The lowest value observed in a cogni-
tively impaired MPS II boy was 423.7 ng/mL.
Urinary GAG Levels were measured in studies HGT-HIT-045, HGT-
HIT-072, and HGT-HIT-073. In the HGT-HIT-072 study, all 9 patients
were receiving intravenous idursulfase treatment, therefore urinary
GAG levels did not reflect true baseline levels in these patients. In the
HGT-HIT-073 study the adult normal subjects had urinary GAG concen-
trations that were within 2 times the upper limit of normal (ULN,
b5.50mg GAG/mmol creatinine). In the HGT-HIT-045 study all patients
had received and tolerated a minimum of 6 months of treatment with
intravenous idursulfase, prior to starting the study, so urinary GAG
levels would not be expected to reflect accurately any baseline levels.
In the HGT-HIT-083 study, no other GAG measurements were taken,
as the study activities were limited to obtaining samples of CSF. None
of studies measured serum GAG levels. For these reasons there is insuf-
ficient data to perform correlation analyses of urinary GAG and CSF GAG
levels in these studies.
4. Conclusions
Dekaban and his colleagues initially reported in 1973 that subjects
with MPS and unimpaired intellects had lower levels of CSF GAGs
than MPS subjects who were mentally impaired [17]. Our study ex-
pands on this and on theHendriksz et al. study that reported differences
between pediatric and adult MPS II patients' CSF GAG levels (the data
from that paper is included here) [16]. This is the first study to under-
take a systematic exploration of CSF GAG levels in MPS II patients and
to compare them to healthy individuals. Our data show that healthy
adults or surrogate-normal children (children who have had a lumbar
puncture for clinical indications other than suspicion of MPS) have CSF
GAG levels that are, on average, 50–70 ng/mL, depending on age, and al-
most always below 200 ng/mL. In contrast, we found that MPS II pa-
tients with cognitive impairment had markedly elevated levels of CSF
GAG,with levels between approximately 400 and 3500 ng/mL and aver-
aging close to 1500 ng/mL. The values observed in both pediatric and
adult patients with the attenuated MPS II phenotype always exceeded
those observed in non-MPS individuals, but overlapped with those ob-
served in the cognitively affected MPS II patients. These data suggest
that CSF GAG levels may be useful diagnostic and prognostic tools for
the classification and management of patients with MPS II, including
the earlier identification of patients at risk for developing cognitive im-
pairment. It is too early, however, to be able to make concrete sugges-
tions as to what levels of GAG in the CSF correlate with what degree
of cognitive impairment, and further data is needed to confirm and ex-
tend the analysis.
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